Objective:To evaluate the diagnostic performance and safety of endoscopic ultrasound-guided fine needle aspiration(EUS-FNA)for biliary lesions and to investigate the factors influencing its accuracy.Methods:A retrospective analysis was performed on the clinical data of patients who underwent EUS-FNA at Chengdu Third People's Hospital between January 2021 and December 2023 for suspected malig-nant biliary strictures or masses,including 22 males and 19 females,with a mean age of 65.9(35.0-89.0)years.Diagnostic performance(sensitivity,specificity,positive predictive value,negative predictive value,and accuracy)and factors influencing these outcomes were evalu-ated.Results:The overall sensitivity of EUS-FNA for diagnosing biliary lesions was 85%,with a specificity of 100%,positive predictive value of 100%,negative predictive value of 33%,and accuracy of 86%.The use of a 25G needle and the presence of solid masses were significant factors influencing the diagnostic accuracy of EUS-FNA.In contrast,the puncture site did not impact diagnostic performance.No EUS-FNA-re-lated adverse events were observed during the follow-up period.Conclusions:EUS-FNA is highly accurate and safe for the diagnosis of bili-ary lesions.The diagnostic accuracy of EUS-FNA significantly improves when using a 25G needle and in the presence of solid biliary masses.

Glioma is the most common primary malignant brain tumor in the adult population,characterized by high incidence and low sur-vival rates.Current standard treatment options exhibit limited efficacy.In recent years,the crucial role of cGAS-STING signaling in tumor im-munity has garnered significant attention.This article systematically reviews the molecular mechanisms of cGAS-STING signaling in glioma and its potential tumor-suppressive effects,providing an in-depth exploration of various STING agonists and their delivery systems targeting this pathway.This review also summarizes the synergistic effects of combining cGAS-STING pathway activation with radiotherapy,chemo-therapy,and immune checkpoint inhibitors,providing substantial references for the development of multimodal comprehensive treatment strategies.

Owing to the insidious onset and limited awareness of early screening,many patients with esophageal squamous cell carcinoma(ESCC)are diagnosed at an advanced stage.Immunochemotherapy is the current standard first-line treatment for advanced ESCC;however,survival outcomes remain suboptimal.Radiotherapy,with its precise local control and potential immunomodulatory effects,is anticipated to act synergistically with immunochemotherapy,offering a novel direction for overcoming survival limitations.This review systematically sum-marizes the progress in the use of radiotherapy as a first-line treatment for advanced ESCC and discusses the synergistic mechanisms,clinical applications,and challenges associated with its combination with immunochemotherapy.

Bruton's tyrosine kinase inhibitors(BTKi)are a class of drugs approved for treating patients with B cell-related hematologic malig-nancies.They function by blocking B cell signaling,thereby affecting the development and proliferation of B cell-related tumors.Research has revealed that Bruton's tyrosine kinase(BTK)is also expressed in other cells,including mast cells,dendritic cells,granulocytes,platelets,and macrophages.Furthermore,BTK's downstream signaling pathways,such as the activation of phospholipase C gamma 2(PLCγ2),Fc re-ceptor signaling path ways,and Toll-like receptor signaling pathways,are associated with various diseases.These mechanisms provide a the-oretical foundation for using BTK in treating diseases other than B cell-related tumors.This article reviews the progress in the application of BTK for non-B-cell malignancies.

Decreased cardiopulmonary function in lung cancer patients significantly negatively impacts survival and quality of life.The con-sensus presented herein was developed by a working group of the Cancer Assessment Society of China Anti-Cancer Association.It is built on evidence-based medicine and expert experience,and aims to standardize the comprehensive assessment of cardiopulmonary function in pa-tients with lung cancer.This consensus defines the core components of comprehensive cardiopulmonary function assessment,emphasizing that assessment should be an integral part of all stages of lung cancer management.Core components include preoperative baseline assess-ment,early postoperative monitoring,dynamic tracking during radiotherapy,systemic medical therapy,and long-term follow-up.This con-sensus provides a standardized reference for the comprehensive assessment of cardiopulmonary function in patients with lung cancer,con-tributing to improved treatment tolerance,optimized therapeutic outcomes,and enhanced long-term prognoses.

Objective:In this study,we aimed to explore the clinical features and factors affecting prognosis by collecting data from patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma(OAML).Methods:Clinical data of 54 patients diagnosed with ocular ad-nexal lymphoma(OAL)at The Second Affiliated Hospital of Soochow University between September 2010 and October 2024 were retro-spectively analyzed.Of these,39(72.2%)had mucosa-asso-ciated lymphoid tissue(MALT)lymphoma,which constituted the focus of this study.The Kaplan-Meier method was used to estimate the progression-free survival(PFS)and overall survival(OS)rates.The Log-rank test was applied to compare survival differences across pathological types and treatment groups.Correlation analysis and univariate Cox regres-sion were conducted to assess the impact of various factors on PFS.Variables with P<0.050 were subsequently included in multivariate Cox regression analysis to identify independent risk factors.Results:Among the 39 patients,the median age at onset was 64 years.Thirty-two and seven patients had unilateral orbital involvement and bilateral orbital involvement,respectively.All the patients underwent surgery.After surgery,the 5-year PFS and the 5-year OS of patients with MALT lymphoma were 54.21%and 100%,respectively.Univariate Cox re-gression analysis indicated that lesion location(P=0.011,hazard ratio[HR]=0.07),remission status after the first treatment(P<0.001,HR=0.082),and EBV infection(P=0.011,HR=0.207)significantly affected PFS.Multivariate regression analysis showed that remission status after the first treatment(P=0.034,HR=0.193)was an independent risk factor for prognosis.Patients who had not achieved complete re-sponse(CR)had a worse prognosis.Conclusions:Remission status after the first treatment is an important prognostic indicator in patients with MALT lymphoma.Close follow-up should be performed for patients who have not achieved complete remission after the first treat-ment.

Objective:This study aimed to investigate the characteristic expression of programmed death-ligand 2(PD-L2)and epithelial-mesenchymal transition(EMT)-related biomarkers in head and neck squamous cell carcinoma(HNSCC)and their mechanism of action in HNSCC metastasis.Methods:Tumor tissue samples from 94 patients with HNSCC were collected from Tianjin Medical University Cancer Hos-pital from January 2018 to July 2023,and their correlation with clinicopathological parameters,including lymph node metastasis,was statist-ically assessed.Western blot was used to detect PD-L2 expression in HNSCC tumor tissues.PD-L2 overexpression and knockdown stably-transfected monoclonal cell lines were generated using lentiviral vectors.Transwell assays were performed to explore the effect of PD-L2 on the invasive migration of the HNSCC cell lines.Additionally,RNA sequencing was used to identify downstream target genes regulated by PD-L2.The expression levels of key EMT markers,including E-cadherin,N-cadherin,and Vimentin,were examined by Western blot to elucidate the molecular mechanism by which PD-L2 promotes tumor cell metastasis through EMT pathway activation.Additionally,RNA sequencing was employed to identify downstream target genes regulated by PD-L2.The expression levels of key EMT markers,including E-cadherin,N-cadherin,and Vimentin,were examined with Western blot analysis to elucidate the molecular mechanism by which PD-L2 promotes tumor cell metastasis through the EMT pathway activation.Results:High expression of PD-L2 is positively correlated with N staging(P<0.05),and elevated PD-L2 expression predicts a poor prognosis in HNSCC patients.Conclusions:PD-L2 regulates the EMT pathway to promote HNSCC metastasis.Targeting PD-L2 is expected to provide a new strategy for the treatment of metastatic HNSCC.

Objective:To investigate the clinicopathological characteristics of patients with early gastric carcinoma with lymphoid stroma(EGCLS).Methods:A retrospective analysis was conducted on 27 consecutive patients with EGCLS who underwent radical surgery at The Second People's Hospital of Changzhou between January 2007 and December 2023.Sixty-nine cases of conventional early gastric carcinoma with matched T stages were randomly selected as controls.Immunohistochemical staining was performed to detect the expression of P53,mismatch repair(MMR)proteins,programmed death-ligand 1(PD-L1),E-cadherin,and human epidermal growth factor receptor 2(HER2)in the study cohort.FISH analysis was conducted on HER2 2+cases,and in situ hybridization was used to detect Epstein-Barr virus(EBV).Res-ults:No significant differences were observed between the two groups in terms of patient sex,age,tumor location,size,ulceration,lymph-ovascular or perineural invasion,tumor budding grade,P53 expression,or MMR protein deficiency.The EGCLS group showed significantly higher proportions of SM2 invasion(88.9%),poor tumor differentiation(70.4%),pushing tumor border(48.1%),PD-L1 positivity(59.3%),Epstein-Barr virus-encoded small RNA(EBER)positivity(55.6%),and abnormal E-cadherin expression(48.1%)compared to the control group(59.4%,46.4%,18.8%,24.6%,1.4%,and 23.2%,respectively;P<0.05).The frequency of lymph node metastasis(7.4%)and the pro-portion of elevated macroscopic type(14.8%)in the EGCLS group were significantly lower than in the control group(30.4%and 40.6%,re-spectively;P<0.05).Lymphovascular invasion,tumor budding grade,and non-EGCLS status were identified as risk factors for lymph node metastasis,with lymphovascular invasion being the only independent risk factor.Conclusions:EGCLS is a rare subtype of early gastric car-cinoma characterized by a low frequency of lymph node metastasis and a high proportion of EBER positivity or MMR protein deficiency.En-doscopic resection or immunotherapy may be preferred treatment options for patients who are not suitable candidates for surgery.

Objective:To investigate the effect of uridine diphosphate ceramide galactosyltransferase 8(UGT8)on colorectal cancer(CRC)cell growth and migration,elucidate an underlying mechanism,and assess the potential regulatory role of SRY-box transcription factor 9(SOX9)on UGT8.Methods:UGT8 and SOX9 mRNA expression levels in CRC tissues,and correlation between their expression levels,were analyzed using GEPIA2,UALCAN,and TIMER 2.0 online databases.UGT8 and SOX9 protein expression in CRC and adjacent tissues was detec-ted using immunohistochemistry,and relationships between their expression and clinicopathological characteristics were analyzed.Impact of UGT8 knockdown on CRC cell proliferation was assessed using a CCK-8 assay,and cell migration was evaluated using Transwell and wound healing assays.Western blot was performed to detect expression of epithelial-mesenchymal transition(EMT)markers(E-cadherin and ZEB1).RT-qPCR and Western blot were used to measure UGT8 mRNA and protein expression levels after SOX9 knockdown.The JASPAR online database was used to assess SOX9 potential for binding to the UGT8 promoter.Results:Bioinformatics analyses revealed significantly higher mRNA expression levels of both UGT8 and SOX9 in CRC tissues than in normal tissues.Positive correlation was observed between expres-sion levels.Immunohistochemistry results showed that tumor UGT8 and SOX9 protein levels were significantly higher than those in adjacent tissues.UGT8 protein level was found to correlates with N stage,and SOX9 protein level correlated with T stage.A positive correlation was observed between UGT8 and SOX9 expression levels.Following UGT8 knockdown,cell proliferation capacity was attenuated and cell migra-tion ability was reduced.E-cadherin expression concurrently increased and ZEB1 expression decreased.RT-qPCR and Western blot results showed that SOX9 knockdown significantly reduced UGT8 mRNA and protein levels.The JASPER website predicts that SOX9 will bind to the UGT8 promoter.Conclusions:UGT8 and SOX9 are highly expressed in CRC tissues,and their expression levels correlate with clinicopatholo-gical features.UGT8 and SOX9 expression levels display significant positive correlation.Mechanistically,UGT8 promotes CRC cell prolifera-tion and migration by facilitating epithelial-mesenchymal transition(EMT).SOX9 enhances UGT8 mRNA and protein expression and may bind to the UGT8 promoter region.

Antibody-drug conjugates(ADCs)represent a major breakthrough in the treatment of human epidermal growth factor receptor-2(HER-2)-positive breast cancer as they are responsible for significantly improving clinical outcomes.However,their widespread use is accom-panied by severe adverse effects that not only impact the quality of life of patients and treatment adherence but also life-threatening,ulti-mately leading to treatment discontinuation.This article systematically reviews the underlying mechanisms and management strategies for ADC-related toxicities in HER-2-positive breast cancer.Additionally,it focuses on key adverse events,including thrombocytopenia,interstitial lung disease,and cardiotoxicity,that are induced by ADCs such as trastuzumab emtansine(T-DM1)and trastuzumab deruxtecan(T-DXd).Based on the clinical evidence,we proposed early monitoring and standardized intervention measures,emphasizing the importance of timely recognition and systematic management to mitigate risks.Furthermore,we explored future directions for optimizing ADC design to reduce their toxicity and provide valuable insights into their safe clinical application.